Microbiota and immune responses in colon cancer: More to learn

Cancer Journal (United States)

Volumn 20, Issue 3, 2014, Pages 232-236

  McAllister, Florencia ^a   Housseau, Franck ^a   Sears, Cynthia L ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

colorectal cancer; immune system; Microbiome

Indexed keywords

CHEMOKINE; CYCLOPHOSPHAMIDE; CYTOKINE; FLUOROURACIL; RNA 16S; TRANSCRIPTION FACTOR;

ADAPTIVE IMMUNITY; ADENOMATOUS POLYP; BACTEROIDES FRAGILIS; CANCER RISK; COLON ADENOMA; COLON CANCER; COLON CARCINOGENESIS; COLON FLORA; COLORECTAL ADENOMA; COLORECTAL CANCER; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FUSOBACTERIUM; GENE DOSAGE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; INFLAMMATION; INTESTINE FLORA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS GALLOLYTICUS; ANIMAL; COLON TUMOR; IMMUNOLOGY; MICROBIOLOGY; MICROFLORA;

ANIMALS; COLONIC NEOPLASMS; HUMANS; MICROBIOTA;

EID: 84901507198     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0000000000000051     Document Type: Review

References (62)

1. Shin HR, Carlos MC, Varghese C. Cancer control in the Asia Pacific region: current status and concerns. Jpn J Clin Oncol. 2012;42:867-881.
2. Lambert R, et al. Survival from digestive cancer in emerging countries in Asia and Africa. Eur J Gastroenterol Hepatol. 2012;24:605-612.
3. Ley RE, et al. Evolution of mammals and their gut microbes. Science 2008;320:1647-1651. (Pubitemid 351931256)
4. Turnbaugh PJ, et al. The human microbiome project. Nature 2007;449: 804-810. (Pubitemid 47598620)
5. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science 2001;292:1115-1118. (Pubitemid 32440925)
6. Backhed F, et al. Host-bacterial mutualism in the human intestine. Science 2005;307:1915-1920. (Pubitemid 40404694)
7. Gordon JI, Knowlton N, Relman DA, et al. Superorganisms and Holobionts. Microbe Magazine. 2013. Forum online. Available at: http://www.microbemagazine. org/index.php?option=com-content&view=article&id= 6300:superorganisms- and-holobionts&catid=1205&Itemid=1464. Accessed May 2, 2014.
8. Hill AB. The environment and disease: association or causation? Proc R Soc Med ( London). 1965;58:295-300.
9. Evans AS. Causation and disease: the Henle-Koch postulates revisited. Yale J Biol Med. 1976;49:175-195.
10. Fredricks DN, Relman DA. Infectious agents and the etiology of chronic idiopathic diseases. Curr Clin Top Infect Dis. 1998;18:180-200. (Pubitemid 128646824)
11. Aries V, et al. Bacteria and the aetiology of cancer of the large bowel. Gut. 1969;10:334-335.
12. Hill MJ, et al. Bacteria and aetiology of cancer of large bowel. Lancet. 1971;1:95-100.
13. Tjalsma H, et al. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol. 2012;10:575-582.
14. Hajishengallis G, Darveau RP, Curtis MA. The keystone-pathogen hypothesis. Nat Rev Microbiol. 2012;10:717-725.
15. Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe. 2014;15:317-328.
16. Lagier JC, et al. Microbial culturomics: paradigm shift in the human gut microbiome study. Clin Microbiol Infect. 2012;18:1185-1193.
17. Dejea C, Wick E, Sears CL. Bacterial oncogenesis in the colon. Future Microbiol. 2013;8:445-460.
18. Boleij A, Tjalsma H. The itinerary of Streptococcus gallolyticus infection in patients with colonic malignant disease. Lancet Infect Dis. 2013;13: 719-724.
19. Boleij A, et al. Clinical importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis. Clin Infect Dis. 2011;53:870-878.
20. Abdulamir AS, Hafidh RR, Bakar FA. Molecular detection, quantification, and isolation of Streptococcus gallolyticus bacteria colonizing colorectal tumors: inflammation-driven potential of carcinogenesis via IL-1, COX-2, and IL-8. Mol Cancer 2010;9:249.
21. Wang X, et al. Enterococcus faecalis induces aneuploidy and tetraploidy in colonic epithelial cells through a bystander effect. Cancer Res. 2008;68: 9909-9917.
22. Yang Y, et al. Colon macrophages polarized by commensal bacteria cause colitis and cancer through the bystander effect. Transl Oncol. 2013;6: 596-606.
23. Wang X, et al. 4-hydroxy-2-nonenal mediates genotoxicity and bystander effects caused by Enterococcus faecalis-infected macrophages. Gastroenterology 2012;142:543-551 e7.
24. Winters MD, et al. Prospective case-cohort study of intestinal colonization with enterococci that produce extracellular superoxide and the risk for colorectal adenomas or cancer. Am J Gastroenterol. 1998;93:2491-2500. (Pubitemid 29018560)
25. Finegold SM, et al. Fecal bacteriology of colonic polyp patients and control patients. Cancer Res. 1975;35(11 Pt. 2):3407-3417.
26. Swidsinski A, et al. Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology 1998;115:281-286. (Pubitemid 28363420)
27. Cuevas-Ramos G, et al. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci USA. 2010;107:11537-11542.
28. Nougayrede JP, et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 2006;313:848-851.
29. Arthur JC, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 2012;338:120-123.
30. Buc E, et al. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PLoS One 2013;8:e56964.
31. Nowrouzian FL, Oswald E. Escherichia coli strains with the capacity for long-term persistence in the bowel microbiota carry the potentially genotoxic pks island. Microb Pathog. 2012;53:180-182.
32. Sears CL. Enterotoxigenic Bacteroides fragilis: a rogue among symbiotes. Clin Microbiol Rev. 2009;22:349-369, Table of contents.
33. Wu S, et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. NatMed. 2009;15:1016-1022.
34. Zitomersky NL, Coyne MJ, Comstock LE. Longitudinal analysis of the prevalence, maintenance, and IgA response to species of the order Bacteroidales in the human gut. Infect Immun. 2011;79:2012-2020.
35. Toprak NU, et al. A possible role of Bacteroides fragilis enterotoxin in the aetiology of colorectal cancer. Clin Microbiol Infect. 2006;12:782-786.
36. Castellarin M, et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012;22:299-306.
37. Kostic AD, et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012;22:292-298.
38. Ahn J, et al. Human gut microbiome and risk for colorectal cancer. J Natl Cancer Inst. 2013;105:1907-1911.
39. Kostic AD, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14:207-215.
40. Rubinstein MR, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe. 2013;14:195-206.
41. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-360. (Pubitemid 38680426)
42. Jinushi M. Yin and yang of tumor inflammation: how innate immune suppressors shape the tumor microenvironments. [published online ahead of print November 22, 2013]. Int J Cancer doi: 10.1002/ijc.28626. Accessed May 2, 2014.
43. Pages F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol. 2008;84:981-987.
44. Pages F, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med.2005;353:2654-2666. (Pubitemid 41817714)
45. Galon J, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-1964. (Pubitemid 44498003)
46. Halama N, et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011;71:5670-5677.
47. Sinicrope FA, et al. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009;137:1270-1279.
48. Salama P, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J ClinOncol. 2009;27: 186-192.
49. Siddiqui SA, et al. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res. 2007;13:2075-2081. (Pubitemid 46649875)
50. Hiraoka N, et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12:5423-5434. (Pubitemid 44497257)
51. Tosolini M, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011;71:1263-1271.
52. Mlecnik B, et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010;138:1429-1440.
53. Baker K, et al. Differential significance of tumour infiltrating lymphocytes in sporadic mismatch repair deficient versus proficient colorectal cancers: a potential role for dysregulation of the transforming growth factor-beta pathway. Eur J Cancer 2007;43:624-631. (Pubitemid 46178541)
54. Qiu H, et al. The prognostic significance of peripheral T-lymphocyte subsets and natural killer cells in patients with colorectal cancer. Hepatogastroenterology. 2009;56:1310-1315.
55. Morris M, Platell C, Iacopetta B. Tumor-infiltrating lymphocytes and perforation in colon cancer predict positive response to 5-fluorouracil chemotherapy. Clin Cancer Res. 2008;14:1413-1417. (Pubitemid 351413923)
56. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
57. Iida N, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013;342:967-970.
58. Viaud S, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013;342:971-976.
59. Soler AP, et al. Increased tight junctional permeability is associated with the development of colon cancer. Carcinogenesis 1999;20:1425-1431. (Pubitemid 29385425)
60. Grivennikov SI, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012;491: 254-258.
61. Bongers G, et al. Interplay of host microbiota, genetic perturbations, and inflammation promotes local development of intestinal neoplasms in mice. J Exp Med. 2014;211:457-472.
62. Gaboriau-Routhiau V, et al. The key role of segmented filamentous bacteria in the coordinatedmaturation of gut helper T cell responses. Immunity 2009;31:677-689.